Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 9:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 216 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bipolar Disorder Severe Clear all
Suspended No phase listed Observational

An Examination of the Performance of QbMobile in Differential Diagnosis Associated With ADHD Symptoms

NCT07329673
View directory record Official record
Conditions
Bi-Polar Disorder, Autism Spectrum Disorder (ASD), Major Depression Disorders, Separation Anxiety Disorder, Social Anxiety Disorder, Generalized Anxiety Disorder (GAD)
Interventions
Digital software application for cognitive performance and activity measurement (QbMobile, investigational device)
Device
Lead sponsor
Qbtech AB
Industry
Eligibility
6 Years to 60 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 4, 2026, 9:54 PM EDT
Completed Not applicable Interventional Results available

Wake Therapy in the Treatment of Depression

NCT01431573
View directory record Official record
Conditions
Major Depressive Disorder, Bipolar Disorder
Interventions
Wake Therapy, light box, Lithium
Behavioral · Device · Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 4, 2026, 9:54 PM EDT
Recruiting Phase 2 Interventional

ALTO-100 in Bipolar Disorder With Depression (BD-D)

NCT06656416
View directory record Official record
Conditions
Bipolar Disorder I or II With a Major Depressive Episode
Interventions
ALTO-100, Placebo
Drug
Lead sponsor
Alto Neuroscience
Industry
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
27
States / cities
Chandler, Arizona • Phoenix, Arizona • Yuma, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 4, 2026, 9:54 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Psychiatric Genotype/Phenotype Project Repository

NCT00762866
View directory record Official record
Conditions
Depressive Disorder, Major, Bipolar Disorder, Psychotic Disorders
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
16 Years to 65 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 4, 2026, 9:54 PM EDT
Active, not recruiting Early Phase 1 Interventional

Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:

NCT03573349
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression, Bipolar Depression
Interventions
Ketamine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 4, 2026, 9:54 PM EDT
Completed Phase 2 Interventional Results available

Reducing Internalized Stigma in People With Serious Mental Illness

NCT01259427
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression With Psychotic Features
Interventions
Ending Self Stigma (ESS), Health and Wellness Group
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Perry Point, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Oct 4, 2026, 9:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Microbiome of Depression & Treatment Response to Citalopram

NCT02330068
View directory record Official record
Conditions
Major Depressive Disorder, Bipolar I and Bipolar II
Interventions
citalopram
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Oct 4, 2026, 9:54 PM EDT
Completed No phase listed Observational

Bipolar Proteomic Assay Validation Study

NCT02746367
View directory record Official record
Conditions
Major Depressive Disorder, Bipolar I and Bipolar II
Interventions
Diagnostic test (LDT)
Other
Lead sponsor
Myriad Genetic Laboratories, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Iowa City, Iowa • Minneapolis, Minnesota • Mason, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Oct 4, 2026, 9:54 PM EDT
Completed Not applicable Interventional

Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis

NCT01570972
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features, Major Depression With Psychotic Features, Psychotic Disorder Not Otherwise Specified (NOS)
Interventions
Group Cognitive Behavioral Therapy, Multifamily Group Psychoeducation
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 35 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 4, 2026, 9:54 PM EDT
Completed Not applicable Interventional Results available

Life Goals Collaborative Care to Improve Health Outcomes in Mental Disorders

NCT01487668
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia, Major Depressive Disorder, Schizoaffective Disorder, Cardiovascular Disease Risk
Interventions
Life Goals Collaborative Care
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 22, 2016 · Synced Oct 4, 2026, 9:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Examination of Glutamate and mGluR5 in Psychiatric Disorders

NCT02727972
View directory record Official record
Conditions
Major Depressive Disorder, Post-Traumatic Stress Disorder, Bipolar Disorder
Interventions
Cognitive Testing, MRI, PET
Behavioral · Other · Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 4, 2026, 9:54 PM EDT
Completed Not applicable Interventional

Comparison of Three Electroconvulsive Therapy (ECT) Techniques for the Treatment of Major Depression

NCT00069407
View directory record Official record
Conditions
Depression
Interventions
Electroconvulsive Therapy
Procedure
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
4
States / cities
Rochester, Minnesota • Newark, New Jersey • Glen Oaks, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2014 · Synced Oct 4, 2026, 9:54 PM EDT
Completed Phase 3 Interventional Results available

The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning

NCT00566735
View directory record Official record
Conditions
Major Depression, Bipolar Depression, Schizoaffective Disorder
Interventions
Razadyne, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 4, 2026, 9:54 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis

NCT04004416
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Healthy, Psychosis, Schizophreniform Disorders, Schizo Affective Disorder, Major Depression With Psychotic Features
Interventions
Placebo and fMRI, Lorazepam and fMRI
Other · Drug
Lead sponsor
University of Michigan
Other
Eligibility
16 Years to 60 Years
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 4, 2026, 9:54 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder

NCT04285515
View directory record Official record
Conditions
Bipolar Depression, Major Depressive Disorder
Interventions
Lumateperone, Placebos
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Garden Grove, California • Oceanside, California • Sherman Oaks, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 4, 2026, 9:54 PM EDT
Not listed Phase 4 Interventional

DIMES - DIgital MEdicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole

NCT03881449
View directory record Official record
Conditions
Schizophrenia, Major Depressive Disorder, Bi-Polar Disorder, Schizo Affective Disorder
Interventions
ABILIFY MYCITE
Combination Product
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 4, 2026, 9:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Imaging in Depression

NCT00050700
View directory record Official record
Conditions
Depression, Bipolar Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 45 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 4, 2026, 9:54 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Comparing Magnetic Seizure Therapy (MST) to Electroconvulsive Therapy (ECT) for Depression in Older Adults

NCT01869374
View directory record Official record
Conditions
Depression, Major Depressive Episode, Bipolar Disorder
Interventions
MagVenture MagPro MST, RUL ECT
Device · Biological
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
55 Years to 90 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 4, 2026, 9:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion

NCT06372210
View directory record Official record
Conditions
Mental Disorder, Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
Interventions
Placebo IEM tablet, Abilify MyCite®, D-Tect Patch
Drug · Device
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Garden Grove, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 4, 2026, 9:54 PM EDT
Recruiting Phase 2 Interventional

The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects

NCT05786066
View directory record Official record
Conditions
Depressive Disorder, Major Depressive Disorder, Bipolar Disorder, Post Traumatic Stress Disorder, Suicidal Ideation
Interventions
Perampanel 6 MG, Ketamine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 4, 2026, 9:54 PM EDT
Completed Not applicable Interventional Results available

Psychosis: Early Detection, Intervention and Prevention

NCT01597141
View directory record Official record
Conditions
Prodromal Schizophrenia, Psychotic Disorders, Severe Bipolar Disorder With Psychotic Features, Severe Major Depression With Psychotic Features
Interventions
Family-aided Assertive Community Treatment, Enhanced standard treatment
Behavioral
Lead sponsor
MaineHealth
Other
Eligibility
12 Years to 35 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 4, 2026, 9:54 PM EDT
Completed Not applicable Interventional Results available

Virtual Reality Job Interview Training in Severe Mental Illness

NCT03049813
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Depressive Disorder
Interventions
Virtual Reality Job Interview Training, Supported Employment (Services as Usual)
Behavioral · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Oct 4, 2026, 9:54 PM EDT
Not listed Phase 3 Interventional

NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation

NCT03396068
View directory record Official record
Conditions
Bipolar Depression, Suicidal Ideation
Interventions
NRX-101, Lurasidone HCl
Drug
Lead sponsor
NeuroRx, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • Hollywood, Florida • Fort Worth, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Oct 4, 2026, 9:54 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode

NCT03692910
View directory record Official record
Conditions
Bipolar Disorder I, Bipolar Disorder II, Major Depressive Episode
Interventions
SAGE-217, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
11
States / cities
Little Rock, Arkansas • Garden Grove, California • Lemon Grove, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 4, 2026, 9:54 PM EDT